Contact us

China National Pharmaceutical
Group Corporation(SINOPHARM)
Address: No.20 Zhichun
Road, Haidian District, Beijing, China
Postal Code: 100191
Fax: 86-10-62033332


Learn more >>

Sinopharm News

The First Oral Factor Xa Inhibitor Xarelto? Launched in China -1

Post Time:2009-06-27 [Large Middle Small] View:
Beijing, June 18, 2009 ? Bayer HealthCare announced today that its novel anticoagulant Xarelto? (rivaroxaban) has been granted approval from the State Food and Drug Administration (SFDA). This approval allows the product to be marketed and sold in China through hospitals, taken as one tablet, once daily for the prevention of venuous blood clots in adult patients undergoing elective (planned) hip or knee replacement surgery, of which the incidence is up to 40%~60% in case of without any preventation, or even cause sudden death due to pulmonary embolism among patients undergoing elective (planned) hip or knee replacement surgery. This product also provide a very simple, effective, and safe treatment approach as the clinical application of current anticoagulants is limited due to their deficiencies.
Prof. Lv Houshan, director of Joint Disease Research Center of Beijing People’s hospital of Peking University, said, “We used to believe that VTE incidence is low in China. However, according to clinical data, the VTE incidence after major orthopaedic surgery in China is about the same as that in western countries. Unfortunately, few Chinese doctors give patients appropriate prophylaxis after major orthopaedic surgery. In the past, hemostatics was used to prevent bleeding before surgery. Now anticoagulant is a revolutionary change from the previous practice. Furthermore, some doctors weren’t aware of the high risk of VTE after major orthopaedic surgery. Therefore, more education work needs to be done.”
“The disadvantage of current anticoagulants is another important reason of the low rate of appropriate prophylaxis,” Said Prof. Lv.
XML 地图 | Sitemap 地图